Literature DB >> 16385106

Mechanisms of neuropathic pain and their implications for the design of clinical trials.

Michael C Rowbotham1.   

Abstract

A mechanism-based approach to treatment is alluring, but numerous practical problems impede its implementation. Although many new therapies have entered clinical trials, and randomized controlled trials have become larger and more sophisticated, pre-trial testing of underlying pain mechanisms is almost never performed for reasons of cost, risk to subjects, time required, and validation of the techniques used. Most registration clinical trials are performed in patients with post-herpetic neuralgia and painful diabetic neuropathy, but without more information on pain mechanisms, it remains uncertain how fully results in those two disorders can be generalized to patients with other types of chronic neuropathic pain. Examples of study designs and potential solutions are presented.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16385106     DOI: 10.1212/wnl.65.12_suppl_4.s66

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  19 in total

Review 1.  Carbamazepine in bipolar disorder with pain: reviewing treatment guidelines.

Authors:  Tahir Rahman; Austin Campbell; Christopher R O'Connell; Kishan Nallapula
Journal:  Prim Care Companion CNS Disord       Date:  2014-10-09

2.  A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain.

Authors:  Barth Wilsey; Thomas Marcotte; Alexander Tsodikov; Jeanna Millman; Heather Bentley; Ben Gouaux; Scott Fishman
Journal:  J Pain       Date:  2008-04-10       Impact factor: 5.820

3.  Efficacy of improgan, a non-opioid analgesic, in neuropathic pain.

Authors:  Phillip J Albrecht; Julia W Nalwalk; Lindsay B Hough
Journal:  Brain Res       Date:  2011-10-08       Impact factor: 3.252

4.  Pain quality predicts lidocaine analgesia among patients with suspected neuropathic pain.

Authors:  Ian R Carroll; Jared W Younger; Sean C Mackey
Journal:  Pain Med       Date:  2010-03-04       Impact factor: 3.750

5.  A randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis.

Authors:  Theodore R Brown; April Slee
Journal:  Int J MS Care       Date:  2015 Mar-Apr

6.  Negative reinforcement reveals non-evoked ongoing pain in mice with tissue or nerve injury.

Authors:  Ying He; Xuebi Tian; Xiaoyu Hu; Frank Porreca; Zaijie Jim Wang
Journal:  J Pain       Date:  2012-05-19       Impact factor: 5.820

7.  Unmasking the tonic-aversive state in neuropathic pain.

Authors:  Tamara King; Louis Vera-Portocarrero; Tannia Gutierrez; Todd W Vanderah; Gregory Dussor; Josephine Lai; Howard L Fields; Frank Porreca
Journal:  Nat Neurosci       Date:  2009-09-27       Impact factor: 24.884

Review 8.  [Treatment options in painful diabetic polyneuropathy].

Authors:  Juan J Archelos
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

9.  Multivariate analysis of chronic pain patients undergoing lidocaine infusions: increasing pain severity and advancing age predict likelihood of clinically meaningful analgesia.

Authors:  Ian Carroll; Raymond Gaeta; Sean Mackey
Journal:  Clin J Pain       Date:  2007-10       Impact factor: 3.442

10.  Mexiletine therapy for chronic pain: survival analysis identifies factors predicting clinical success.

Authors:  Ian R Carroll; Kimberly M Kaplan; Sean C Mackey
Journal:  J Pain Symptom Manage       Date:  2008-01-28       Impact factor: 3.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.